Prostacyclin Infusion in Patients with Acute Myocardial Infarction (Preliminary Report)
- 28 April 1983
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 308 (17) , 1032-1033
- https://doi.org/10.1056/nejm198304283081716
Abstract
To the Editor: Prostacyclin (prostaglandin I2) has been suggested as a suitable agent for protecting ischemic myocardium against necrosis. The reasons for this would be not only its platelet antiaggregatory1 and coronary vasodilator2 actions but also its suggested cytoprotective effect.3 In view of these potentially beneficial effects of prostacyclin, we are studying the effect of its infusion in patients with acute myocardial infarction. After a 30-day follow-up of five patients who constituted an open pilot series (preceding the more comprehensive, randomized part of the investigation), we found the results sufficiently notable to warrant a preliminary report.Four of . . .Keywords
This publication has 3 references indexed in Scilit:
- Role of prostacyclin in the preservation of ischemic myocardial tissue in the perfused cat heart.Circulation Research, 1980
- Prostacyclin (PGX) is the endogeneous metabolite responsible for relaxation of coronary arteries induced by arachidonic acidProstaglandins, 1977
- An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregationNature, 1976